Lok Lam Ngai

9PUBLICATIONS
28CO-AUTHORS
Medical virologyRegenerative medicine (incl. stem cells)Respiratory diseasesMedical mycologyMedical bacteriology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 10, 2025
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.

Lukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp

|Sep 03, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.

Tim R Mocking, Lukas H Haaksma, Tom Reuvekamp

|Feb 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.

Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog

|Dec 20, 2024
Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models.

Tim R Mocking, Angèle Kelder, Tom Reuvekamp

|Aug 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).

Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman

|Jan 25, 2024
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.

Jesse M Tettero, Maaike E Heidinga, Tim R Mocking

Pageof 2

Frequent Collaborators

7 joint publications

Costa Bachas

5 joint publications

Jacqueline Cloos

5 joint publications

Arjan A van de Loosdrecht

4 joint publications

Tom Reuvekamp